Cited by 12Celiac Disease Research and ManagementPharmacy and Medical PracticesPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Gluten in pharmaceutical products: a scoping review

Open access
Lizano-Díez, Irene, Mariño, Eduardo L., Modamio, Pilar·2021·Systematic Reviews

Abstract

Background: Celiac disease (CD) is one of the most common gluten-related disorders. Although the only effective treatment is a strict gluten-free diet, doubts remain as to whether healthcare professionals take this restriction into consideration when prescribing and dispensing medicines to susceptible patients. This scoping review aimed to find out the current evidence for initiatives that either describe the gluten content of medicines or intend to raise awareness about the risk of prescribing and dispensing gluten-containing medicines in patients with CD and other gluten-related disorders. Methods: A scoping review was conducted using three search strategies in PubMed/MEDLINE, TripDatabase and Web of Science in April 2021, following the PRISMA extension for scoping reviews (PRISMA-ScR). References from included articles were also examined. Two researchers screened the articles and results were classified according to their main characteristics and outcomes, which were grouped according to the PCC (Population, Concept and Context) framework. The initiatives described were classified into three targeted processes related to gluten-containing medicines: prescription, dispensation and both prescription and dispensation. Results: We identified a total of 3146 records. After the elimination of duplicates, 3062 articles remained and ultimately 13 full texts were included in the narrative synthesis. Most studies were conducted in the US, followed by Canada and Australia, which each published one article. Most strategies were focused on increasing health professional’s knowledge of gluten-containing/gluten-free medications (n = 8), which were basically based on database development from manufacturer data. A wide variability between countries on provided information and labelling of gluten-containing medicines was found. Conclusion: Initiatives regarding the presence of gluten in medicines, including, among others, support for prescribers, the definition of the role of pharmacists, and patients’ adherence problems due to incomplete labelling of the medicines, have been continuously developed and adapted to the different needs of patients. However, information is still scarce, and some aspects have not yet been considered, such as effectiveness for the practical use of solutions to support healthcare professionals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13643-021-01772-9

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow diagram of study selection
Fig. 1 Flow diagram of study selectionCC BY · PubMed Central
Fig. 2 Evidence map of identified literature
Fig. 2 Evidence map of identified literatureCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 19

  1. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62:43–52. · DOI · Paper page
  2. Catassi C, Gatti S, Lionetti E. World perspective and celiac disease epidemiology. Dig Dis. 2015;33:141–6. · DOI
  3. Elli L, Villalta D, Roncoroni L, et al. Nomenclature and diagnosis of gluten-related disorders: a position statement by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Dig Liver Dis. 2017;49:138–46. · DOI
  4. Mearns ES, Taylor A, Boulanger T, et al. Systematic literature review of the economic burden of celiac disease. Pharmacoeconomics. 2019;37:45–61. · DOI
  5. Mangione RA, Patel PN. Caring for patients with celiac disease: the role of the pharmacist. J Am Pharm Assoc. 2008;48:e125–35. · DOI
  6. Patel DG, Krogh CM, Thompson WG. Gluten in pills: a hazard for patients with celiac disease. Can Med Assoc J. 1985;133:114–5.
  7. Challen RG, O’Shannassy RM. Gluten content of Australian pharmaceutical products. Med J Aust. 1987;146:91–3. · DOI
  8. King AR. The Impact of celiac sprue on patients’ medication choices. Hosp Pharm. 2009;44:105–6. · DOI
  9. King AR. Gluten content of the top 200 medications of 2008: A follow-up to the impact of celiac sprue on patients’ medication choices. Hosp Pharm. 2009;44:984–92. · DOI
  10. King AR. Gluten content of the top 200 medications: follow-up to the influence of gluten on a patient’s medication choices. Hosp Pharm. 2013;48:736–43. · DOI
  11. Cruz JE, Cocchio C, Lai PT, et al. Gluten content of medications. Am J Health Syst Pharm. 2015;72:54–60. · DOI
  12. King AR. The influence of gluten on a patient’s medication choices. Hosp Pharm. 2010;45(11):841–3. · DOI
  13. Crowe JP, Falini NP. Gluten in pharmaceutical products. Am J Health Syst Pharm. 2001;58:396–401. · DOI
  14. Mangione RA, Patel PN. Pharmaceutical care of celiac disease. US Pharm. 2011;36:30–3.
  15. Avena-Woods C, Mangione RA, Wu WK. Exploring the community pharmacist’s knowledge of celiac disease. Am J Pharm Educ. 2018;82:100–5. · DOI
  16. Miletic ID, Miletic VD, Sattely-Miller EA, Schiffman SS. Identification of gliadin presence in pharmaceutical products. J Pediatr Gastroenterol Nutr. 1994;19:27–33. · DOI
  17. Urwin H, Wright D, Twigg M, et al. Early recognition of coeliac disease through community pharmacies: a proof of concept study. Int J Clin Pharm. 2016;38(5):1294–300. · DOI
  18. Plogsted S. Medications and celiac disease - tips from a pharmacist. Pract Gastroenterol. 2007;31:58–64.
  19. Esteban S, Podder N, Cruciani R. Celiac disease: not all medications are contaminated with gliadin. J Pain Symptom Manage. 2006;31:195–6. · DOI

Cited by

Sorted by citations

Metadata

Authors
Lizano-Díez, I., Mariño, E. L., & Modamio, P.
Affiliations
Universitat de Barcelona (ES)
Corresponding author
Modamio, Pilar
Venue
Systematic Reviews
Published
2021-08-07
Volume
10
Issue
1
Pages
218-218
ISSN
2046-4053 (ISSN-L)
OpenAlex
W3190780165
Cited by
12
References
3
Citations by year
2026: 1 · 2025: 5 · 2024: 3 · 2023: 3
FWCI
1.37
Type
journal article
Language
en
Open access
Locations
  • Systematic Reviews (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Gastroenterology › Celiac Disease Research and Management
  • Health Sciences › Health Professions › Pharmacy › Pharmacy and Medical Practices
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
gluten, pharmaceutical products, celiac disease, gluten-related disorders, drug labeling, drug prescribing, dispensing, pharmacist role, health professionals' knowledge, medication adherence
MeSH terms
Celiac Disease, Pharmaceutical Preparations, Glutens, Humans, Pharmacists, Diet, Gluten-Free

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review